{{Rsnum
|rsid=4764695
|Chromosome=12
|position=102363335
|Orientation=plus
|GMAF=0.4141
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 24.8 | 46.0 | 29.2
| HCB | 15.3 | 46.7 | 38.0
| JPT | 10.6 | 42.5 | 46.9
| YRI | 7.5 | 35.6 | 56.8
| ASW | 7.0 | 31.6 | 61.4
| CHB | 15.3 | 46.7 | 38.0
| CHD | 11.0 | 56.0 | 33.0
| GIH | 40.6 | 47.5 | 11.9
| LWK | 3.7 | 35.8 | 60.6
| MEX | 36.2 | 37.9 | 25.9
| MKK | 17.3 | 49.4 | 33.3
| TSI | 20.8 | 54.5 | 24.8
| HapMapRevision=28
}}{{PMID Auto
|PMID=20484221
|Title=A Comprehensive Analysis of Common IGF1, IGFBP1 and IGFBP3 Genetic Variation with Prospective IGF-I and IGFBP-3 Blood Levels and Prostate Cancer Risk Among Caucasians
|OA=1
}}

{{PMID Auto
|PMID=17300730
|Title=Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study.
|OA=1
}}

{{PMID Auto
|PMID=18596909
|Title=IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3).
|OA=1
}}

{{PMID Auto
|PMID=19551864
|Title=Genetic variation and circulating levels of IGF-I and IGFBP-3 in relation to risk of proliferative benign breast disease.
|OA=1
}}

{{PMID Auto
|PMID=24177231
|Title=The RTK/ERK Pathway is associated with Prostate Cancer Risk on the SNP level: a pooled analysis of 41 sets of data from case-control studies
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}